175 related articles for article (PubMed ID: 36271155)
1. Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study.
Gu X; Yu X; Shi G; Li Y; Yang L
Abdom Radiol (NY); 2023 Jan; 48(1):220-228. PubMed ID: 36271155
[TBL] [Abstract][Full Text] [Related]
2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
3. A computed tomography-based radiomics signature for predicting expression of programmed death ligand 1 in head and neck squamous cell carcinoma.
Zheng YM; Yuan MG; Zhou RQ; Hou F; Zhan JF; Liu ND; Hao DP; Dong C
Eur Radiol; 2022 Aug; 32(8):5362-5370. PubMed ID: 35298679
[TBL] [Abstract][Full Text] [Related]
4. Multiparameter spectral CT-based radiomics in predicting the expression of programmed death ligand 1 in non-small-cell lung cancer.
Zheng XX; Ma YQ; Cui YQ; Dong SS; Chang FX; Zhu DL; Huang G
Clin Radiol; 2024 Apr; 79(4):e511-e523. PubMed ID: 38307814
[TBL] [Abstract][Full Text] [Related]
5. Correlation of CT parameters and PD-L1 expression status in gastric cancer.
Xu M; Ren T; Deng J; Yang J; Lu T; Xi H; Yuan L; Zhang W; Zhou J
Abdom Radiol (NY); 2024 Apr; 49(4):1320-1329. PubMed ID: 38436699
[TBL] [Abstract][Full Text] [Related]
6. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
[TBL] [Abstract][Full Text] [Related]
7. Potential value of CT radiomics in the distinction of intestinal-type gastric adenocarcinomas.
Wang Y; Liu W; Yu Y; Han W; Liu JJ; Xue HD; Lei J; Jin ZY; Yu JC
Eur Radiol; 2020 May; 30(5):2934-2944. PubMed ID: 32020404
[TBL] [Abstract][Full Text] [Related]
8. A CT-based radiomics signature for preoperative discrimination between high and low expression of programmed death ligand 1 in head and neck squamous cell carcinoma.
Zheng YM; Zhan JF; Yuan MG; Hou F; Jiang G; Wu ZJ; Dong C
Eur J Radiol; 2022 Jan; 146():110093. PubMed ID: 34890937
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study.
Xie W; Jiang Z; Zhou X; Zhang X; Zhang M; Liu R; Zheng L; Xin F; Lu Y; Wang D
Acad Radiol; 2023 Jul; 30(7):1317-1328. PubMed ID: 36369191
[TBL] [Abstract][Full Text] [Related]
10. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
Wen Q; Yang Z; Dai H; Feng A; Li Q
Front Oncol; 2021; 11():620246. PubMed ID: 34422625
[TBL] [Abstract][Full Text] [Related]
11. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
Park KJ; Lee JL; Yoon SK; Heo C; Park BW; Kim JK
Eur Radiol; 2020 Oct; 30(10):5392-5403. PubMed ID: 32394281
[TBL] [Abstract][Full Text] [Related]
12. Preoperative prediction for lauren type of gastric cancer: A radiomics nomogram analysis based on CT images and clinical features.
Sun Z; Jin L; Zhang S; Duan S; Xing W; Hu S
J Xray Sci Technol; 2021; 29(4):675-686. PubMed ID: 34024809
[TBL] [Abstract][Full Text] [Related]
13. Radiomic signature based on CT imaging to distinguish invasive adenocarcinoma from minimally invasive adenocarcinoma in pure ground-glass nodules with pleural contact.
Jiang Y; Che S; Ma S; Liu X; Guo Y; Liu A; Li G; Li Z
Cancer Imaging; 2021 Jan; 21(1):1. PubMed ID: 33407884
[TBL] [Abstract][Full Text] [Related]
14. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
15. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
16. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment.
Liang Z; Huang A; Wang L; Bi J; Kuang B; Xiao Y; Yu D; Hong M; Zhang T
Aging (Albany NY); 2022 Jan; 14(2):907-922. PubMed ID: 35073519
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response to neoadjuvant chemotherapy in advanced gastric cancer: A radiomics nomogram analysis based on CT images and clinicopathological features.
Tan X; Yang X; Hu S; Ge Y; Wu Q; Wang J; Sun Z
J Xray Sci Technol; 2023; 31(1):49-61. PubMed ID: 36314190
[TBL] [Abstract][Full Text] [Related]
18. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.
Wen Q; Yang Z; Zhu J; Qiu Q; Dai H; Feng A; Xing L
Onco Targets Ther; 2020; 13():12003-12013. PubMed ID: 33244242
[TBL] [Abstract][Full Text] [Related]
20. CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.
Wang Y; Liu W; Yu Y; Liu JJ; Xue HD; Qi YF; Lei J; Yu JC; Jin ZY
Eur Radiol; 2020 Feb; 30(2):976-986. PubMed ID: 31468157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
